Please sign in to follow a disease.
Stevens-Johnson syndrome
MONDO:0018229Stevens-Johnson syndrome is a limited form of toxic epidermal necrolysis characterized by destruction and detachment of the skin epithelium and mucous membranes involving less than 10% of the body surface area.
Also known as: Dermatostomatitis, Stevens Johnson type, Stevens Johnson syndrome, Stevens-Johnson syndrome, susceptibility to, erythema multiforme major, hypersensitivity syndrome, carbamazepine-induced, susceptibility to, severe cutaneous adverse reaction, susceptibility to, toxic Epidermal necrolysis, susceptibility to
16 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Lab-grown stem cells may restore damaged eye surfaces
Disease control CompletedThis study tests whether a graft made from a patient's own or donor stem cells can repair the cornea's surface in people with limbal stem cell deficiency, a condition that causes pain, scarring, and vision loss. A small biopsy of limbal tissue is taken from a healthy eye or donor…
Phase: NA • Sponsor: Veerle Van Gerwen • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a white blood cell booster heal a rare skin emergency?
Disease control CompletedThis study tested whether G-CSF (a drug that boosts white blood cells) can help heal toxic epidermal necrolysis, a rare but severe skin reaction. Ten patients were randomly assigned to receive G-CSF or a placebo for five days. Researchers measured how fast the skin healed and loo…
Phase: PHASE4 • Sponsor: University of Liege • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Small study tests drug for rare, Life-Threatening skin condition
Disease control CompletedThis study tested a drug called etanercept against a placebo for people with severe skin reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis). Only 2 adults took part. The goal was to see if the drug speeds up skin healing and to learn more about the disease.
Phase: PHASE3 • Sponsor: Vanderbilt University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Arthritis drug shows promise for rare, Life-Threatening skin conditions
Disease control CompletedThis pilot study tested the drug tofacitinib (XELJANZ) in 20 adults with Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN), rare and severe skin reactions often caused by medications. The main goal was to see how quickly the skin healed completely. Researchers al…
Phase: NA • Sponsor: Chang Gung Memorial Hospital • Aim: Disease control
Last updated Jun 26, 2026 18:13 UTC
-
AI could cut skin specialist wait times, study hints
Knowledge-focused CompletedThis study tested an artificial intelligence algorithm designed to help primary care doctors decide whether a patient with a skin condition really needs to see a dermatologist. Researchers enrolled 200 adults with skin problems and had their doctors take photos of the affected ar…
Sponsor: AI Labs Group S.L • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC